Clinical efficacy of first-line immunotherapy plus anti-angiogenesis targeted therapy in the treatment of advanced hepatocellular carcinoma / 中华消化外科杂志

Hepatocellular carcinoma has a high morbidity and mortality, which has seriously harmed human health. Several targeted therapies have been approved for the first- and second-line treatment of advanced hepatocellular carcinoma. The emergence of immunotherapy has brought the treatment of hepatocellular carcinoma into a new era. Targeted and immunotherapeutic agents have synergistic effects in mechanism, also the combination of these two therapies has been clinically beneficial to patients with advanced hepatocellular carcinoma. At the same time, in addition to the systemic therapy of targeted combined immunological, applying appropriate local therapy can provide a longer survival period or even a chance of cure for that some patients. The authors introduce the diagnosis and treatment of a case of advanced hepatocellular carcinoma who achieved pathological complete remission by first-line immunotherapy combined with anti-angiogenesis targeted therapy.

Fine mapping of heterozygosity loss on chromosome 20q11-13 in sporadic colorectal cancer / 中华消化外科杂志

Objective To refine the loss of heterozygosity(LOH) on chromosome 20q11-13 and identify the new tumor suppressor gene(s) in colorectal tumorigenesis. Methods From 1998 to 1999, 83 patients with colorectal cancer had been admitted to Shanghai First People's Hospital. Tumor tissues and adjacent normal mucosal tissues were collected. Ten polymorphic microsatellite markers were analyzed on chromosome 20 and another 10 markers were applied on chromosome 20q11-13 in 83 cases of colorectal and normal DNA by PCR. PCR products were eletrophoresed on an ABI 377 DNA sequencer. Genesean 3.1 and Genotyper 2.1 software were used for LOH scanning and analysis. Results We observed a distinct region of frequent allelic deletions on chromosome, another 10 polymorphric microsatellite markers were applied to 20q11-13 and 2 minimal regions of frequent LOH were established, that is to say 20q11.2, 20q12. Tumor suppressor genes E2F1, PMP24 and MAFB were found in the regions of 20q11.2 and 20q12. Conclusion Through our detailed deletion mapping studies, we have found 2 critical and precise regions, which must contain one or more unknown tumor suppressor gene (s) on colorectal cancer.